NCT04493853: Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
- State
- Under way
- Phase
- Phase 3
- People
- 1,012 taking part
- Started
- 13 Jul 2020
- Primary completion
- 7 Oct 2024
- Arms
- Capivasertib + Abiraterone
- Results
- Posted on the registry
- 13 Jul 2020: Trial started
- 30 Jul 2020: Trial registered
- 10 Sep 2026: Trial results posted